Top advocacy goals the American Society of Nephrology (ASN) has championed throughout the 118th Congress have been included in draft text for a large end-of-year legislative package on Capitol Hill.
For people taking popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis) after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.
Swine Viral Disease Conference Celebrates Industry Leaders, Students
Huntsman Cancer Institute researchers have identified a gene variant found in a high-altitude Andean population that may predict severity of diseases and responses to treatments for patients with certain types of blood cancer.
In November, Lurie Children’s and Northwestern University co-hosted the 2024 T1D Exchange Learning Session in Chicago. The T1D Exchange Quality Improvement Collaborative (QIC) brings together clinics across the United States, connecting experts that collectively treat over 100,000 individuals with Type 1 diabetes.
The UCLA team will be presenting original research related to novel therapeutics, functional imaging, immunotherapy-related complications, socioeconomic disparities, and genomic interception strategies for patients with high risk for breast cancer recurrence.
Patients with multiple myeloma are living longer thanks to a host of new immunotherapies and targeted drugs. But there is still no cure for the disease. Physician-scientists at Sylvester Comprehensive Cancer Center are working to change that, and will present research findings at the 2024 annual meeting of the American Society of Hematology (ASH).
Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.
About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy that might boost the effectiveness of existing DLBCL therapies, a team from Roswell Park has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax. Their findings, to be presented during a talk today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California, provide strong preclinical evidence that adding venetoclax to standard treatment may improve outcomes in patients with treatment-resistant B-cell lymphomas.
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a talk at the 66th American Society of Hematology (ASH) Annual Meeting. The study, led by Jens Hillengass, MD, PhD, and Janine Joseph, MS, MBA, presents new evidence documenting that targeted exercise regimens can alleviate fatigue, improve sleep and reduce pain, offering new hope for enhancing quality of life in cancer care.
The results of two important lymphoma studies led by experts at Roswell Park Comprehensive Cancer Center will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California. Lymphoma is a type of blood cancer that causes white blood cells called lymphocytes to grow out of control and behave abnormally.
ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive a allogeneic hematopoietic stem cell transplant for acute myeloid, however, if they can access the treatment, are equally likely to benefit from transplant as patients with more education and higher income, according to a new study from Fred Hutch Cancer Center presented at the annual meeting of the American Society of Hematology.
A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates — FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center, presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 4).
Researchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.
Cedars-Sinai experts in pharmacy services attending the Dec. 8-12 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting 2024 in New Orleans are available for interviews about the latest developments in patient safety and pharmacy practice.
The Hong Kong Institute for Advanced Study (HKIAS) hosted its Annual General Meeting (AGM) on 19 November 2024, bringing together Senior Fellows from across the globe to discuss strategic advancements in research and international collaboration. Chaired by our HKIAS Chairman Professor Serge Haroche, the meeting focused on strengthening global partnerships between the City University of Hong Kong (CityUHK) and the home institutions of our Senior Fellows, recruiting leading scholars to HKIAS, and preparing for the Institute's 10th-anniversary celebration in 2025, etc.
20221027104337.jpg&width=400&height=400)
Severe hemophilia A is a genetic disorder that prevents blood from clotting properly, posing a constant risk of dangerous bleeding episodes. Infants with severe hemophilia A (HA) are at risk of brain bleeds, which can lead to serious long-term brain damage. Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right